Building the route from aging research to clinical evidence

# Building the route from aging research to clinical evidence OCTOBER 11, 2026 Senior FDA officials said this month that aging and longevity will appear in the agency's next regulatory science agenda. That gives companies working on aging therapies a clearer signal about how the agency is thinking, though it is not yet a path to approval. A promising intervention needs a way to demonstrate its value. The regulatory conversation around aging is increasingly concerned with that practical work: populations, endpoints, safety, and the evidence that links them. According to Lifespan.io, the remarks came at the 2026 Aging Research and Drug Discovery Meeting (ARDD) in Boston. The panel was titled "Matching Clinical Trials of Therapeutics & Regulatory Mandates." It included four FDA officials and was moderated by Andrew Brack of ARPA-H. The most concrete news was about the agency's Focus Areas of Regulatory Science (FARS). Steven Kozlowski, the FDA's Chief Scientist, said the document sets out "high-level principles on areas that are very, very important to us; aging and longevity will be one of those topics." He gave a tentative release target of fiscal year 2027, which began on October 1. The previous version came out several years ago. Lowell Zeta, Deputy Commissioner for Strategic Initiatives, called the moment "a defining moment, an inflection point for the future of FDA." He said the topic matters to the agency and to the wider Department of Health and Human Services. The panel did not announce a dedicated approval pathway for aging itself. It described how sponsors might show broader effects. Jeffrey Siegel, Director of the Office of Drug Evaluation Sciences, outlined two approaches. One is to build evidence that a treatment benefits several age-related conditions. The other draws on the idea of intrinsic capacity. It would measure decline across multiple physical and mental capacities in a defined population and show that treatment slows it. For companies, the practical point is what comes first. Justin Penzenstadler, Acting Associate Director of the Office of Cardiology, Hematology, Endocrinology, and Nephrology, expects early trials that could support approval to focus on age-related comorbidities or mortality. Collecting functional measures alongside those outcomes could help set metrics for later trials. A strategic reading is that early programs may be judged on conventional disease or survival endpoints, not on aging as such. That is our interpretation, not an FDA statement. There is a clear limit on claims. A broader aging claim needs evidence beyond a drug's established benefits. Penzenstadler said that if a cardiometabolic drug extends survival through its known cardiovascular effects, that alone does not show broader geroprotective activity. Companies hoping to market a drug as slowing aging will need data that goes further. Safety also shapes who gets enrolled. Penzenstadler said, "We're thinking about potentially treating somebody for thirty years to derive a couple-year benefit." He therefore favors initial trials in older, higher-risk groups, where the benefit-risk balance "is a bit more straightforward." For developers, that points to older populations as the likelier starting point. Biomarkers could shorten trials, but only if they are shown to reliably reflect benefit. Siegel drew a line between prognostic biomarkers, which predict future risk, and surrogate endpoints. In his words, a surrogate "may also be prognostic, but it has the additional feature that it changes with treatment, and that change reflects the clinical benefit downstream." The panel discussed collecting both clinical outcomes and candidate biomarkers in trials to build that evidence. Penzenstadler's top recommendation was a pre-competitive consortium to develop "a cookbook of biomarkers" for use in trials. If companies agree on compatible designs up front, they can pool results and build the case for validation. He called it "probably the number one thing that is actionable." His second suggestion was regular, structured meetings among regulators, researchers and industry. Lifespan.io noted that some existing efforts fit the two approaches Siegel described. The proposed TAME trial would examine multiple age-related diseases. XPRIZE Healthspan focuses on muscle, cognitive and immune function. The Biomarkers of Aging Consortium reflects the same need for shared measurement. The panel also named a contact point. Penzenstadler said his clinical review office is responsible for aging as an indication. He encouraged sponsors to submit actual protocols and supporting evidence through the Investigational New Drug (IND) process, so the FDA has something specific to assess and respond to. For the market, the near-term effect is clarity of process, not a change in rules. Companies that can run trials in older, higher-risk groups, and that collect biomarker data alongside clinical outcomes, appear best placed to use this opening. Shared biomarker work could also favor groups willing to cooperate before they compete. These are our readings of the panel, and the FDA has not committed to them. WHAT TO WATCH NEXT The release of the updated FARS document, targeted for fiscal year 2027, and whether any sponsor submits an aging-focused protocol through the IND process. Shared measurement work may be one of the most productive places to collaborate. It can make separate experiments more informative to one another. Source: Lifespan.io ---